![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sJfV7OaWcbhbxFfr9RjjGmmUUgneSwk39mULLlV2grZLOMtf8E3TJD1l0PwlLoYnpMASm94apqde3UxnmF4naLB9hXHNpjj58aJ-_VoNY=s0-d){kind=small}
PUBLIC RELEASE DATE: 1-Nov-2013
[
]
ShareContact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding receptors, called Fc receptors, on other immune cells bind anti-CD20 on coated B cells, which induces B cell deletion through a mechanism that is not clearly understood. In this issue of the Journal of Clinical Investigation, Philippe Bousse and colleagues at the Pasteur Institute in Paris described the fate of B cells in live mice after treatment with anti-CD20 antibodies. Bousse and his group found that B cells circulating through the liver were the first ones depleted after treatment and that B cells in circulation were more susceptible to deletion than those stationary in the spleen or lymph nodes. The researchers used intravital two-photon microscopy to follow B cells in the liver as they halted near specialized Fc receptor-bearing cells called Kupffer cells. The Kupffer cells bound and consumed the anti-CD20-coated B cells. The study assigns a vital role to liver Kupffer cells in deleting B cells and describes techniques that may be used to improve the effectiveness of anti-CD20 therapy
###
TITLE:
The mechanism of anti-CD20mediated B cell depletion revealed by intravital imaging
AUTHOR CONTACT:
Philippe Bousso
Institut Pasteur, Paris, FRA
Phone: 33 1 45 68 85 51; Fax: ; E-mail: bousso@pasteur.fr
View this article at: http://www.jci.org/articles/view/70972?key=b0390c54a360d17753f4
[
Share]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
PUBLIC RELEASE DATE: 1-Nov-2013
[
]
ShareContact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding receptors, called Fc receptors, on other immune cells bind anti-CD20 on coated B cells, which induces B cell deletion through a mechanism that is not clearly understood. In this issue of the Journal of Clinical Investigation, Philippe Bousse and colleagues at the Pasteur Institute in Paris described the fate of B cells in live mice after treatment with anti-CD20 antibodies. Bousse and his group found that B cells circulating through the liver were the first ones depleted after treatment and that B cells in circulation were more susceptible to deletion than those stationary in the spleen or lymph nodes. The researchers used intravital two-photon microscopy to follow B cells in the liver as they halted near specialized Fc receptor-bearing cells called Kupffer cells. The Kupffer cells bound and consumed the anti-CD20-coated B cells. The study assigns a vital role to liver Kupffer cells in deleting B cells and describes techniques that may be used to improve the effectiveness of anti-CD20 therapy
###
TITLE:
The mechanism of anti-CD20mediated B cell depletion revealed by intravital imaging
AUTHOR CONTACT:
Philippe Bousso
Institut Pasteur, Paris, FRA
Phone: 33 1 45 68 85 51; Fax: ; E-mail: bousso@pasteur.fr
View this article at: http://www.jci.org/articles/view/70972?key=b0390c54a360d17753f4
[
Share]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-11/joci-lti102513.php
Tags: River Phoenix jonbenet ramsey Johnny Manziel krispy kreme Joanna Krupa
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.